Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Authors

Institutions

Publication Details

Journal
European Journal Of Haematology
Published
2026-03-02
DOI
https://doi.org/10.1111/ejh.70150
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab

Andrea Messori
European Journal Of Haematology
Chronic Lymphocytic Leukemia Research
article

Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab

Andrea Messori
article en

Abstract

The data that support the findings of this study are available from the corresponding author upon reasonable request.

European Journal Of Haematology
Istituto Nazionale di Documentazione Innovazione e Ricerca Educativa (IT)
Zero hunger
Openalex Percentile: Top 37%
Chronic Lymphocytic Leukemia Research
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Updating Efficacy of First‐Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab — Andrea Messori · European Journal Of Haematology (2026) | TGRS Research Map | TGRS